Pharmaceuticals News and Research

RSS

Safety of bird flu drug Tamiflu in children questioned

A prominent Japanese researcher reporting on the bird flu drug Tamiflu says the drug may not be safe for children.

20 Apr 2009

Jet lag disrupts sleep by throwing two neural centers out of sync

New research by scientists in the U.S. has revealed that the disrupted sleep which results from jet lag and shift work occurs in two separate but linked groups of neurons below the hypothalamus at the base of the brain.

19 Apr 2009

Vion Pharmaceuticals' NDA for Onrigin accepted for FDA review

Vion Pharmaceuticals, Inc. has announced that the New Drug Application (NDA) for its lead oncology therapeutic Onrigin (laromustine) Injection has been accepted for review by the U.S. Food and Drug Administration (FDA).

16 Apr 2009

Star Scientific reports on patent application for Zero-Nitrosamine tobacco curing process

Star Scientific and its wholly-owned subsidiary, Rock Creek Pharmaceuticals ("Rock Creek"), have reported on their continuing efforts to lessen the harm linked with tobacco use.

16 Apr 2009

Jet lag disturbs sleep by upsetting internal clocks in 2 neural centers

Jet lag is the bane of many travelers, and similar fatigue can plague people who work in rotating shifts.

16 Apr 2009

GlaxoSmithKline and Pfizer team up to form HIV company

Pharmaceutical companies GlaxoSmithKline and Pfizer today announced an "innovative agreement" to pool their HIV assets creating a new world-leading, specialist HIV company.

16 Apr 2009

Separating the good from the bad

Scientists at MIT and Brown University studying how marine bacteria move recently discovered that a sharp variation in water current segregates right-handed bacteria from their left-handed brethren, impelling the microbes in opposite directions.

15 Apr 2009

Rochester scientist wins major award for Alzheimer's research

A Rochester researcher whose work has opened up a whole new avenue in Alzheimer's disease research has received a major prize from the American Academy of Neurology.

15 Apr 2009

Rib-X granted patent for novel oxazolidinone in China

Rib-X Pharmaceuticals, Inc. ("Rib-X" or the "Company"), a development-stage company focused on the discovery and development of novel antibiotics for the treatment of antibiotic-resistant infections, today announced the issuance of a key antibiotic patent in China.

15 Apr 2009

Federal funding for partnership to combat infectious diseases

Oregon Health & Science University and the University of Washington, along with a number of partner institutions across the Northwest, have received federal funding to form a regional research center aimed at combating emerging or re-emerging infectious diseases that pose a serious threat to human health.

15 Apr 2009

Non-drug treatment of Alzheimer's disease: Long-term benefit not proven

Whether people with Alzheimer's disease benefit in the long term from non-drug treatment interventions remains an unanswered question.

15 Apr 2009

Mycophenolate mofetil may be an alternative therapy for lupus nephritis

Lupus is a rare but serious disease that mainly affects women of child-bearing age and occurs when the body's immune system goes awry, damaging a variety of organs.

15 Apr 2009

FDA grants Oasmia's Paclical orphan drug designation for ovarian cancer in U.S.

Oasmia Pharmaceutical, Uppsala, Sweden, has been granted Orphan Drug designation by the USA FDA of Paclical for the treatment of ovarian cancer.

14 Apr 2009

Mylan confirms first-to-file patent challenge relating to Xeloda

Mylan Inc. has confirmed that the company and its subsidiary Mylan Pharmaceuticals Inc. have been sued by Hoffmann-La Roche Inc. in connection with the filing of an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) for Capecitabine Tablets, 150 mg and 500 mg, the generic version of Xeloda Tablets, a chemotherapy treatment for breast and colorectal cancer.

14 Apr 2009

Vaccine for Enterotoxigenic E. coli developed

A Michigan State University researcher has developed a working vaccine for a strain of E. coli that kills 2 million to 3 million children each year in the developing world.

14 Apr 2009

Optimer Pharmaceuticals receives production patent for Fidaxomicin

Optimer Pharmaceuticals, Inc. has announced that the United States Patent and Trademark Office issued a production patent (U.S. Patent No. 7,507,564) covering steps used in the manufacture of fidaxomicin, which is currently in its second Phase 3 clinical trial for the treatment of Clostridium difficile infection, or CDI.

13 Apr 2009

Health Canada approves Simponi (golimumab) for rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis

Centocor Ortho Biotech Inc. and Schering-Plough Corporation has announced that Health Canada has granted approval of Simponi (golimumab) as a once-monthly, subcutaneous therapy for the treatment of moderately to severely active rheumatoid arthritis (RA), active psoriatic arthritis (PsA) and active ankylosing spondylitis (AS).

13 Apr 2009

New therapy for metastatic prostate cancer shows promise

A new therapy for metastatic prostate cancer has shown considerable promise in early clinical trials involving patients whose disease has become resistant to current drugs.

12 Apr 2009

FDA stops Neilgen Pharmaceuticals and Advent Pharmaceuticals from making unapproved drugs

The U.S. Food and Drug Administration today announced that it had obtained a permanent injunction barring Neilgen Pharmaceuticals Inc. of Westminster, Md., its parent company, Advent Pharmaceuticals, Inc. (Advent), of East Windsor, N.J., and two of their officers, Bharat Patel and Pragna Patel, from manufacturing and distributing any unapproved, adulterated or misbranded drugs.

12 Apr 2009